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Measurements were performed to assess the dose equivalent outside a primary proton treatment
field, using a silicon-on-insulator SOI microdosimeter. The SOI microdosimeter was placed on the
surface of an anthropomorphic phantom and dose equivalents were determined as a function of
lateral distance from a typical passively scattered and modulated prostate treatment field. Measure-
ments were also completed within a polystyrene plate phantom as a function of depth for a distance
of 5 cm from the field edge, as function of lateral distance from field edge at two different depths,
and as a function of distance from the distal edge on the central beam axis. The dose equivalent at
the surface of the anthropomorphic phantom decreases from 3.9 to 0.18 mSv/Gy when the lateral
distance from the proton field edge increases from 2.5 to 60 cm. Measurements along the proton
depth dose distribution at a constant distance of 5 cm from the primary field edge indicate a
decrease in dose equivalent as a function of depth, with a 38% decrease relative to the surface dose
at a depth of 5 cm in polystyrene. Measurements completed as a function of lateral distance from
the primary field at two separate depths within polystyrene illustrate a convergence of the dose
equivalent at approximately 20 cm from the primary field edge. Past the distal edge of the spread-
out Bragg peak dose equivalents decrease exponentially for increasing distance, with an initial
value of 1.6 mSv/Gy at 0.6 cm from the distal edge. Silicon microdosimetry measurements were
also compared with published results obtained utilizing different measurement techniques. This
study demonstrates the applicability of SOI microdosimetry in determining the dose equivalent
outside proton treatment fields, and provides valuable information on the dose equivalent both at
the surface and at depth experienced by prostate cancer patients treated with protons. © 2007
American Association of Physicists in Medicine. DOI: 10.1118/1.2759839
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I. INTRODUCTION
Presently one of the major health risks mankind faces is can-
cer. Projections are that one in three people will suffer from
this disease or side effects of its treatment at one stage in
their life.1 Because of the deleterious effects that cancer and
often current treatment forms are having on the human popu-
lation, better treatment techniques are constantly being
sought. Besides surgery, external beam radiation therapy is a
mainstay of cancer treatment and cure. Over the last two
decades highly conformal radiation therapy techniques have
been developed, including intensity modulated photon radio-
therapy IMRT and radiotherapy utilizing protons and car-
bon ions. One drawback of these techniques is that they may
increase the contribution of lower doses to large volumes of
normal tissues outside the target volume.2
High energy protons are an important innovation in exter-
nal beam radiation therapy, providing highly conformal dose
distributions, thus sparing normal tissues through the benefits
afforded by the Bragg peak. These dose distributions provide
a smaller integral dose to surrounding normal tissues when
compared with conventional x-ray treatments. Despite the
dose sparing properties of protons and heavy ions, they do
have the potential to produce unwanted dose outside the pri-
mary field due to secondary particles such as neutrons
through inelastic nuclear interactions with the beam modify-
ing devices and tissues traversed. This is of concern as neu-
trons are known to be more effective than photons and high
energy protons at producing radiation induced cancers.2 The
primary beam is also scattered as it traverses the patient,
contributing additional unwanted dose outside the primary
treatment field.
The production of secondary particles with therapeutic
proton beams and the delivery of unwanted dose equivalent
outside the treatment field is closely related to the delivery
technique employed.2 Proton delivery techniques can be cat-
egorized as passive or active in the delivery of a uniform
dose to the treatment volume. Passive techniques, which
have been most commonly used in the clinical setting, in-
cluding prostate cancer treatment,3,4 spread the beam later-
ally using a combination of gold and Lexan foils5 and in
depth by using a rotating plastic wheel.6 The beam is then
collimated by brass or Cerrobend® apertures and its penetra-
tion depth is varied by means of a wax bolus. Active
techniques,7–10 currently only practiced in a clinical situation
at the Paul Scherrer Institute PSI, employ a magnetically
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guided proton pencil beam in combination with dynamic
changes of beam energy and beam intensity during treat-
ment. Comparatively, passive beam delivery techniques pro-
vide a larger source of secondary neutrons due to the addi-
tional presence of scattering foils, modulator, aperture, and
bolus.
Measurements of out-of-field doses delivered in both ac-
tive and passive clinical proton modalities are scarce11–13 and
have primarily concentrated on the measurement of neutrons
with Bonner spheres and bubble detectors. Additional mea-
surements are required and should be performed systemati-
cally for different beam delivery techniques utilizing the
same method of measurement. We have approached this
problem utilizing silicon-based microdosimetry, which is
characterized by a superior spatial resolution and directly
provides information on the dose equivalent using estab-
lished quality factors.14 The measurements reported here pro-
vide information on the depth and lateral distance depen-
dence of the dose equivalent for a passively scattered proton
beam used in a typical prostate cancer treatment. Silicon mi-
crodosimetry measurements were compared with published
results obtained utilizing different measurement techniques.
II. EXPERIMENTAL METHOD
This study utilized a solid-state microdosimeter with
silicon-on-insulator SOI technology as illustrated in Fig. 1.
The large size of tissue equivalent proportional counters
TEPC, classically used in microdosimetry measurements,15
made it unsuitable for measurements in small increments
close to the primary proton treatment field edge and within a
phantom structure. The SOI microdosimeter, presented in de-
tail in Ref. 16, comprised an array of 4800 silicon cells, each
with a physical size of 3030 m, on a single chip with a
sensitive volume SV thickness of 10 m. This small size
allowed for accurate placement within the phantom structure
and close to the primary field edge. The application of SOI
microdosimeters in therapeutic neutron radiation fields has
been studied in detail, and good agreement was observed
between the derived microdosimetry spectra of both the SOI
and TEPC devices.17,18 This device has also been used ex-
tensively in hadron and proton therapy, particularly in pri-
mary beam microdosimetry measurements.16,17,19–21
In this experimental setup, the SOI microdosimeter, pre-
amplifier, and accompanying electronics were situated within
an aluminum probe assembly to allow for a low noise envi-
ronment to be achieved. The wall thickness of the probe was
900 m, with a 4 m aluminum window immediately in
front of the microdosimeter to allow for the transport of low
range secondaries into the microdosimeter. The microdosim-
eter probe was housed within a Perspex probe holder to en-
able accurate placement throughout the experiment. This
setup is described further in Ref. 21. A 0.5 mm thick poly-
ethylene converter affixed immediately anterior to the SOI
microdosimeter allowed for the conversion of neutrons to
recoil protons that could then be detected within the SV.
Such converters have been employed in previous neutron
and mixed field measurements with this device.17,20
All measurements were completed using a patient specific
aperture-bolus combination, and proton energy of 225 MeV
to simulate a typical radiation field delivered in a clinical
prostate case. The maximum aperture diameter was 8 cm
both in lateral and vertical direction. Additional measure-
ments were also completed in some cases using a 13 cm
diameter circular aperture quality assurance or QA aperture
with no bolus present to demonstrate the effect of aperture
size and bolus on the dose equivalent. To conduct a thorough
study of the dose equivalent delivered outside the treatment
field, four separate experimental configurations were used,
each measuring a different aspect of the radiation field. In the
first case, the patient was simulated with an anthropomorphic
phantom Rando® Phantom, The Phantom Laboratory, Sa-
lem, NY housed within a regular patient immobilization
system Fig. 2. The microdosimeter MD was placed on the
phantom surface at the height of the central axis, and micro-
dosimetry measurements were performed to determine the
FIG. 1. Basic SOI diode array struc-
ture of the microdosimeter developed
at the CMRP, University of
Wollongong.
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change in dose equivalent as a function of increasing lateral
distance from the field edge.
Additional measurements were conducted with the an-
thropomorphic phantom replaced with a stack of polystyrene
blocks. Using this experimental setup, three measurement
series were completed Fig. 3. First, the MD was placed at
different depths within the polystyrene phantom at a distance
of 5 cm from the field edge to estimate the change in dose
equivalent as a function of depth within the patient series
M1. Measurements were also completed to assess the
change in dose equivalent as a function of lateral distance
from the field edge at different depths within the polystyrene
phantom series M2. Finally, measurements were completed
to assess the dose equivalent beyond the distal edge of the
spread-out Bragg peak SOBP series M3, with the distal
edge being defined as the point where the primary dose
reached 50%. In all cases, dose equivalent was normalized to
the proton dose delivered at isocenter.
II.A. Determination of dose equivalent
The dose equivalent H was defined in Ref. 14 to char-
acterize the effects of low doses of ionizing radiation on
health. It is defined by the ICRU as
H = QD , 1
where Q is the average quality factor of the radiation field
and D is absorbed dose in tissue at a given point of interest.
The unit of dose equivalent is the Sievert Sv, with Q speci-
fied by ICRU Report 40.22
In this study, the method outlined in Refs. 14 and 15 was
used in the determination of H with specified Q values,
which are dependent on lineal energy. The conversion of
measured microdosimetry spectra Fig. 4 to dose equivalent
proceeded in two steps: 1 calculation of absorbed dose to
tissue at each point of measurement; 2 calculation of the
dose-averaged quality factor at that point.
Microdosimetric data were acquired as energy deposition
spectra fE vs E, where fE is the relative frequency of
events and E the energy determined from the charge col-
lected within in a single silicon SV. Energy deposition events
were corrected for 0.8 charge collection efficiency23 and then
used to calculate the absorbed dose to silicon by integrating
over the spectrum Eq. 2,
DSi =
0
fEEdE
SiVncells
, 2
where ncells is the number of SVs in a given array used
4800,16 V is the volume of a 303010 m3 individual
detection element, and Si the density of silicon.
24 The tissue-
equivalent TE dose DTE can then be determined by using
the ratio of total stopping powers of protons for silicon, SSi
and tissue STE Ref. 25 referred to in this document as TE
conversion factor ,
DSi
DTE
=
SSi
STE
=  . 3
From previous research16,17,19 and comparisons with TEPCs,
the most appropriate value of  was determined to be 
=0.63, which was used in this work.
The first step in calculating the fraction of the dose-
average quality factor is to convert the fE spectra into a
lineal energy spectra using the average chord length l,
FIG. 3. Experimental setup for experimental measurements within a poly-
styrene phantom. Note the three separate measurement series conducted
with this experimental setup. M1 determined the change in dose equivalent
as a function of depth; M2 provided the change in dose equivalent as a
function of distance from the field edge within the polystyrene phantom; and
M3 indicated the change in dose equivalent past the distal edge.
FIG. 2. Experimental setup for surface measurements as a function of dis-
tance from the field edge.
FIG. 4. Examples of distributions ob-
tained using the SOI microdosimeter
including a fE vs E distribution;
b fy vs y distribution; c ydy vs
y distribution.
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l =
4V
A
, 4
where V is the volume and A the surface area of the SV. For
the 303010 m3 sensitive volume the average chord
length is 19.05 m. Note the use of the TE conversion fac-
tor to calculate the average chord length in tissue. Dividing E
by l in the energy deposition spectra provides the lineal
energy spectra. The normalized dose-weighted lineal energy
distribution is given by
dy =
yfy
yf
, 5
where
yf = 
0

yfydy 6
is the frequency averaged lineal energy. Note that dy gives
the fraction of total absorbed dose in the interval y ,y+dy.
In order to determine dose equivalent, a y-dependent qual-
ity factor Qy was introduced as prescribed by ICRU Report
40.22 From the dy distribution, the dose equivalent at that
point in space can be determined using Eq. 7,
H = DTE
0

Qydydy = QavgDTE, 7
where Qavg is the average quality factor.
III. RESULTS
Figure 5 presents the results of dose equivalent values on
the surface of the anthropomorphic phantom as a function of
distance from the incident proton field edge. It is evident
from these results that the aperture and bolus used within a
typical prostate cancer patient treatment increased the dose
equivalent by a factor of 2–4 when compared to the 13 cm
circular QA aperture without bolus. The increased collima-
tion present in the case of the patient specific aperture re-
sulted in greater interaction of the primary proton beam with
the collimation material, leading to elevated doses outside
the treatment field. Dose equivalent values of approximately
4 and 2 mSv/Gy were found at 2.5 cm from the edge of the
primary beam for the patient specific aperture/bolus combi-
nation and the QA aperture, respectively. Sub-mSv readings
were detected at distances greater than 10 and 20 cm from
the field edge in the case of the QA aperture and patient
specific combination, respectively. At a distance of 60 cm
from the field edge the dose equivalent for the patient spe-
cific setup was 0.176 mSv/Gy, which would result in a total
dose equivalent at this point of 14 mSv assuming a total dose
delivery of 80 Gy to isocenter, which is the typical integral
dose used in patient treatments.
Figure 6 shows results of measurements that were com-
pleted to assess the change in dose equivalent as a function
of depth in a polystyrene phantom at 5 cm lateral distance
from the patient specific proton field series M1. For com-
parison, the central axis depth-dose distribution of the pri-
mary proton beam, as measured by a Markus chamber, is
also shown and normalized to the dose at isocenter 100%.
Initial dose equivalent values at the surface of the phantom
decreased by 38% after traversing 5 cm of phantom material.
Figure 7 displays the lateral distance dependence of dose
equivalent at two different depths within the polystyrene
phantom measurement series M2. Measurements were
completed at the plateau region and the level of the SOBP.
The dose equivalent decreased with increasing distance from
the field edge, similarly to what was measured at the phan-
tom surface Fig. 5, however with a more gradual falloff.
Moreover, the falloff is less pronounced at the level of the
SOBP compared to the shallower depth, which leads to a
convergence of the two curves at a lateral displacement from
the field edge of 20 cm. This would indicate that secondaries
produced inside the phantom contributed increasingly to the
dose equivalent.
FIG. 5. Results as measured with the SOI microdosimeter for both the pa-
tient specific aperture/bolus portal and the 13 cm circular QA aperture with
no bolus present.
FIG. 6. Dose equivalent at 5 cm from the field edge compared with the depth
dose distribution of the proton beam as measured along the central axis with
a Markus chamber. The proton dose is expressed as a percentage with 100%
dose delivered at isocenter.
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Figure 8 displays the dose equivalent past distal edge of
the SOBP in the polystyrene phantom measurement series
M3. The dose equivalent in the case of the typical prostate
treatment investigated here was 1.6 mSv/Gy at 0.6 cm from
the distal edge, and this value decreased exponentially with
increasing distance from the distal edge. Fitting an exponen-
tial function to this trend resulted in the following relation-
ship for the dose equivalent in mSv:
H = 1.65e−0.1081x, 8
where x is the distance in cm from the distal edge.
The average quality factor is valuable as it provides infor-
mation on the types and abundances of radiation present.
This information is presented in Fig. 9 as a function of lateral
distance from the treatment field edge measured at the sur-
face of the anthropomorphic phantom, past the distal edge of
the SOBP in the homogeneous polystyrene phantom mea-
surement series M3, and also as a function of depth in poly-
styrene measurement series M1. The average quality factor
increased from 2 to 7 at a distance of 2.5 and 60 cm from the
field edge, respectively. Figure 9b shows that the average
quality factor past the SOBP remained relatively constant at
an approximate value of 6.5. In this region, high energy pri-
mary protons were not present and the radiation field com-
prised of relatively low energy neutrons produced both from
the beam-modifying/monitoring devices and within the
phantom. Figure 9c indicates that the average quality factor
does not change significantly in the proton plateau region,
with a stable value of approximately 2.5 registered. At the
level of the SOBP, the average quality factor increases to
values of 5–6.
IV. DISCUSSION
In this work, we have utilized a microdosimeter based on
SOI technology to measure the depth and lateral distance
dependence of the dose equivalent for a passively scattered
proton beam used in a typical prostate cancer treatment. Un-
like conventional TEPC devices, the SOI microdosimeter
comprises an array of truly microscopic detection elements.
This allows for faster data acquisition through the use of
multiple SVs, good spatial resolution, and placement inside
phantoms. The microdosimetry method also provides a more
accurate estimation of dose equivalent using an established
relationship between lineal energy and quality factor. This is
particularly advantageous in mixed radiation field measure-
ments.
SOI microdosimetry has certain limitations that need to be
considered when evaluating the uncertainty of the measure-
ments presented in this work. The lower level detection limit
of the SOI device is approximately 0.8−1 keV/m,
whereas the y values in the Qy distribution extend down to
0.1 keV/m. This limitation does not produce a significant
error in the dose equivalent because the Q value is less than
1 in this region. The main source of error in these measure-
ments arises from the TE conversion factor, which is derived
from the ratio of stopping powers. This factor covers a wide
range of recoil proton energies from 0.1–200 MeV; hence,
the value for each individual particle can lie from 0.5–0.8 as
shown in Fig. 10. Previous work with protons and alpha
particles has found best agreement using a value of 0.63. By
using this value, the systematic error introduced in the data
presented here may be up to about ±15%. Additional work,
including Monte Carlo simulations, is necessary to further
reduce this uncertainty for proton therapy applications.
Measurements in polystyrene provided information on the
change in dose equivalent Figs. 6 and 7 and average quality
factor Fig. 9 as a function of depth and lateral displacement
from the field edge. Figure 6 indicates that the initial dose
equivalent values at the surface of the phantom decreased by
38% after traversing 5 cm of phantom material. This leads to
the conclusion that many secondary particles produced
within the passive scattering and collimation system do not
penetrate to a great depth within the phantom. Such particles
are probably thermal neutrons; however, Monte Carlo simu-
FIG. 7. Assessment of the dose equivalent as a function of lateral distance
from the field edge at different depths within the polystyrene phantom.
FIG. 8. Dose equivalent values past the distal edge of the SOBP.
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lations would be needed to determine this with certainty.
Figure 9a shows that at the surface of the phantom the
quality factor increases with increasing distance from the lat-
eral field edge. This indicates that, close to the field edge,
scattered neutrons of higher energy and lower linear energy
transfer LET made up a substantial portion of the dose
equivalent, however, further from the field edge lower energy
neutrons predominate resulting in higher average quality fac-
tors. In the region past the SOBP on the central beam axis the
quality factor remains practically constant Fig. 9b. In this
region, high energy primary protons are not present and the
radiation field comprises of relatively low-energy neutrons
produced both from the beam-modifying/monitoring devices
and within the phantom. Figure 9c indicates that at a lateral
distance of 5 cm from the field edge the average quality
factor did not change significantly in the proton plateau re-
gion, with a stable value of approximately 2.5 registered
while the dose equivalent decreases. At the level of the
SOBP, the average quality factor increased to values of 5–6
indicating the presence of higher LET particles, which are
predominantly slowing protons.
The SOI results presented here provide an estimate of the
dose equivalent both at the surface and at depth that a pros-
tate cancer patient will experience during proton therapy.
They show that dose equivalent values are of the order of a
few mSv/Gy within 10 cm of the treatment volume Figs. 5
and 7 and appear to level off at about 0.2 mSv for larger
distances from the treatment volume Fig. 7. These dose
equivalent values compare favorably to those experienced by
patients from IMRT treatments2 and cone beam CT imaging
that is increasingly used for image guided radiation
therapy.26
It is important when applying existing technology to a
new mode of measurement to benchmark results against ex-
isting data in this field. Figure 11 illustrates the comparison
of results from other centers using different measurement
techniques. At the Midwest Proton Radiotherapy Institute
MPRI, neutron doses were measured with a neutron bubble
FIG. 9. Average quality factor values
for a points lateral to the treatment
field edge at the surface of the anthro-
pomorphic phantom; b points past
the SOBP within the polystyrene
phantom; and c as a function of
depth in polystyrene at 5 cm from the
primary field edge. In each case, the
aperture and bolus combination was
that for a typical prostate patient.
FIG. 10. Ratio of proton stopping powers for silicon and tissue Ref. 25.
The region of interest in this case was approximately 0.1–200 MeV.
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detector and a passively scattered and modulated proton
beam of 12 cm range in water. The field size in this instance
was 10 cm in diameter with an 8 cm modulation delivered to
the midline of an anthropomorphic phantom. Measurements
were made as a function of distance from the proton field
edge within the phantom, with the detector situated within
the abdomen to determine the scattered neutron dose at the
location of a fetus. Measurements were completed for two
snout sizes 10 and 20 cm, with the 20 cm results presented
here. The Harvard Cyclotron Laboratory HCL data were
derived on the 160 MeV beamline used for patient treatments
utilizing Bonner spheres for the detection of neutrons. A Lu-
cite phantom 26 cm in diameter and 24 cm in length rep-
resented the patient, while the primary proton radiation field
had a cross-sectional area of 55 cm2 and a range of 16 cm
with a modulation of 8.2 cm. The neutron dose equivalent
per unit proton absorbed dose was measured as a function of
vertical distance below isocenter. Finally, the data from the
Paul Scherrer Institute PSI provide information on the sec-
ondary neutron dose delivered during a spot-scanning treat-
ment. Again, this study utilized Bonner spheres as the radia-
tion detection apparatus with an incident beam of 177 MeV
and no range shifter plates in the beam path. A water phan-
tom with 0.5 cm thick Lucite walls was used to simulate the
patient. The values of effective neutron dose were measured
laterally from the water phantom at the level of the treatment
volume, not the surface of the phantom as in the case pre-
sented here.
Despite the difference in experimental conditions and
measurement techniques, the agreement between the data is
good. Of note, the equivalent doses measured with the spot-
scanning beam were consistently lower than the other data,
in particular at distances greater than 50 cm. This is consis-
tent with the fact that the spot-scanning system does not
contain beam modifying devices such as apertures and scat-
tering foils which contribute neutrons to the radiation field
outside the primary treatment field. The results from PSI,
HCL, and MPRI consisted of lower incident proton energies
than the measurements completed with the SOI microdosim-
eter, which may have a bearing on the results as lower inci-
dent proton energies have in turn lower cross sections for
inelastic reaction.
V. CONCLUSION
This study has shown the applicability of the SOI micro-
dosimeter in determining the dose equivalent outside proton
treatment fields, and has provided valuable information of
the dose equivalent both at the surface and at depth experi-
enced by prostate cancer patients treated with protons. Fur-
ther studies utilizing the SOI microdosimeter should be con-
ducted with therapeutic proton fields generated with both
passive and active beam delivery techniques under otherwise
equivalent conditions and for different clinical treatment sce-
narios including pediatric cancers. It will also be useful in
such studies to compare the response of SOI detector to other
microdosimetric and neutron measurement techniques.
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